Oridonin inhibits breast cancer cell proliferation and migrationthrough suppressing COX-2 expression
DOI:
https://doi.org/10.61173/m65c1y93Keywords:
oridonin, breast cancer, COX-2, proliferation, migrationAbstract
Oridonin, a biologically active substance isolated from the plant Rabdosia rubescens, is recently reported to have an
inhibitory effect on breast cancer. However, its mechanism is still unclear. According to previous findings, increased
COX-2 expression has been associated with a higher incidence of breast cancer. Therefore, this study aims to explore
whether oridonin inhibits cell proliferation and migration by suppressing the expression of COX-2 in human breast
cancer cells MDA-MB-231 in vitro and in vivo conditions. In this study, human breast cancer cells MDA-MB-231
will be treated with increasing concentrations and for various durations with oridonin to investigate whether oridonin
inhibits cell migration, decrease proliferation, and reduce tumors in mice through suppressing the expression of COX2. A positive control is a taxol. A negative control is medium. Cell migration will be tested by Transwell assay. The
proliferation will be detected by MTT assay. The western-blotting assay will be used for COX-2. In nude mice, the in
vivo anti-tumor efficacy of oridonin will be examined. The study’s result will provide insight into the effect of oridonin
on the proliferation and migration of human breast cancer cells MDA-MB-231. It will also provide reference for the
mechanism of how oridonin inhibits breast cancer and lay the foundation for future studies on the molecular basis of
oridonin’s pharmacological activity in the future.
References
[1] CP W, E W, BW S. World Cancer Report: Cancer Research for Cancer Prevention. Accessed November 10, 2022. https:// publications.iarc.fr/Non-Series-Publications/World-Cancer- Reports/World-Cancer-Report-Cancer-Research-For-Cancer- Prevention-2020
[2] Niero EL, Rocha-Sales B, Lauand C, et al. The multiple facets of drug resistance: one history, different approaches. J Exp Clin Cancer Res. 2014;33(1):37.
[3] Ku CM, Lin JY. Anti-inflammatory effects of 27 selected terpenoid compounds tested through modulating Th1/Th2 cytokine secretion profiles using murine primary splenocytes. Food Chemistry. 2013;141(2):1104-1113.
[4] Song M, Liu X, Liu K, et al. Targeting AKT with oridonin inhibits growth of esophageal squamous cell carcinoma in vitro and patient derived xenografts in vivo. Mol Cancer Ther. 2018;17(7):1540-1553.
[5] Lu J, Chen X, Qu S, et al. Oridonin induces G2/M cell cycle arrest and apoptosis via the PI3K/Akt signaling pathway in hormone-independent prostate cancer cells. Oncol Lett. 2017;13(4):2838-2846.
[6] Wang Y, Lv H, Dai C, Wang X, Yin Y, Chen Z. Oridonin Dose-Dependently Modulates the Cell Senescence and Apoptosis of Gastric Cancer Cells. Evid Based Complement Alternat Med. 2021;2021:5023536.
[7] Xu L, Bi Y, Xu Y, et al. Oridonin inhibits the migration and epithelial-to-mesenchymal transition of small cell lung cancer cells by suppressing FAK-ERK1/2 signalling pathway. J Cell Mol Med. 2020;24(8):4480-4493.
[8] Xia S, Zhang X, Li C, Guan H. Oridonin inhibits breast cancer growth and metastasis through blocking the Notch signaling. Saudi Pharm J. 2017;25(4):638-643.
[9] Asghar K, Loya A, Rana IA, et al. Association between Cyclooxygenase-2 and Indoleamine 2,3-Dioxygenase Expression in Breast Cancer Patients from Pakistan. Asian Pac J Cancer Prev. 2019;20(11):3521-3525.
[10] Kim YY, Lee EJ, Kim YK, et al. Anti-cancer effects of celecoxib in head and neck carcinoma. Mol Cells. 2010;29(2):185-194.
[11] Harris RE, Casto BC, Harris ZM. Cyclooxygenase-2 and the inflammogenesis of breast cancer. World J Clin Oncol. 2014;5(4):677-692.
[12] Li C, Wang Q, Shen S, Wei X, Li G. Oridonin inhibits VEGF-A-associated angiogenesis and epithelial-mesenchymal transition of breast cancer in vitro and in vivo. Oncol Lett. 2018;16(2):2289-2298.
[13] Peng Y, Wang Y, Tang N, et al. Andrographolide inhibits breast cancer through suppressing COX-2 expression and angiogenesis via inactivation of p300 signaling and VEGF pathway. J Exp Clin Cancer Res. 2018;37(1):248.
[14] Li X, Zhang CT, Ma W, Xie X, Huang Q. Oridonin: A Review of Its Pharmacology, Pharmacokinetics and Toxicity. Front Pharmacol. 2021;12:645824.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
